Navigation Links
Response Genetics Reports Second Quarter 2007 Financial Results
Date:8/19/2007

dividends 6,097,579 -

Deferred revenue, net of current

portion 3,320,000 1,621,489

Total liabilities 13,762,049 8,811,527

Commitments and contingencies

Stockholders' equity (deficit)

Series B Convertible Preferred

Stock, $0.01 par value; 1,038,048

issued and outstanding (liquidation

preference of $9 per share, or

$9,342,432 plus accrued but unpaid

dividends) at December 31, 2006 10,380 -

Series A Junior Convertible

Preferred Stock, $0.01 par value;

500,000 issued and outstanding

(liquidation preference of $5 per

share, or $2,500,000) at December

31, 2006 5,000 -

Common stock, $0.01 par value;

20,000,000 and 50,000,000 shares

authorized; 2,726,320 and

10,239,256 shares issued and

outstanding 27,263 102,393

Additional paid-in capital 9,722,273 34,311,892

Accumulated deficit (15,267,284) (18,509,649)

Accumulated other comprehensive

income (loss) - (4,208)

Total stockholders' (deficit)

equity (5,502,368) 15,900,428

Total liabilities and stockholders'

(deficit) equity $ 8,259,681 $ 24,711,955

RESPONSE GENETICS, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended Six Months

June 30, Ended June 30,

2006 2007 2006 2007

Revenue $ 738,150 $ 1,495,618 $ 2,007,125
'/>"/>

SOURCE Response Genetics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Wisconsin court affirms damages in Innogenetics, Abbott patent case
6. Third Wave licenses Innogenetics tech to settle lawsuit
7. Symposium examines the effect of race on genetics and disease
8. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
9. Sonic Foundry reports GAAP loss as Q2 revenues rise
10. Fiserv reports $113.5 million in Q1 profit
11. Third Wave reports net loss of $18.9M for 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... June 25 Lixte,Biotechnology Holdings (OTC Bulletin Board: ... Disorders and Stroke (NINDS), National,Institutes of Health (NIH) ... and Development Agreement (CRADA) to develop,drugs for the ... March,2006 was extended through September 2009., Dr. ...
... titled “Avanta AC™ Advanced Ceramics Solutions as ... white paper outlines the challenges in manufacturing ... as well as the advantages of SACHEM’s ... are critical to a variety of leading ...
... (OTCBB:BTIM) and BioTime’s wholly-owned subsidiary Embryome Sciences, ... agreement with International Stem Cell Corporation (OTCBB:ISCO) ... (Lifeline) to jointly produce and distribute hundreds ... cell lines, along with corresponding data and ...
Cached Biology Technology:Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 2Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 3 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 3 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 4 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 5
(Date:4/18/2014)... adds a twist to the story of how barnyard chickens ... 21 in the journal Proceedings of the National Academy ... chickens that lived 200-2300 years ago in Europe, researchers report ... have looked far different from the chickens we know today. ... associate with modern domestic chickens -- such as their yellowish ...
(Date:4/17/2014)... Ill. A drug under clinical trials to treat ... broad-spectrum drugs that act against various bacteria, fungal infections ... by University of Illinois chemists and collaborators. , Led ... team determined the different ways the drug SQ109 attacks ... to target other pathogens from yeast to malaria ...
(Date:4/17/2014)... suggests that fish consumption advisories for expecting mothers ... contaminants like persistent organic pollutants (POPs). , ... including University of Toronto Scarborough PhD student Matt ... different levels of environmental contamination, a mother,s compliance ... the body influenced exposure in her children. , ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2
... sp. DN1 , which may prove to be ... snow fields of the Rocky Mountains. Research examining this new ... DN1 was found to grow at temperatures approaching freezing ... sp. DN1 produces the highest quantity of lipids when ...
... into two species, the one-humped dromedary and the two-humped ... camels are precious in desert regions throughout the world. ... makes them ideally suited for transportation. In addition, camels ... without food and water. Despite the extremely arid conditions, ...
... AURORA, Colo. (May 27, 2013) A new study ... caused a significant spike in the number of young ... and beverages. "We have seen an increase in ... of drugs laws in Colorado," said George Wang, MD, ...
Cached Biology News:Decoding the genome of the camel 2Surge in children accidentally eating marijuana-laced foods 2Surge in children accidentally eating marijuana-laced foods 3
Desmosomal Protein Immunogen: Full length, native protein purified from human epidermal keratins. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: